These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37792623)

  • 1. Osimertinib in Resected EGFR-Mutated NSCLC. Reply.
    Tsuboi M; Herbst RS; Wu YL
    N Engl J Med; 2023 Oct; 389(14):1342. PubMed ID: 37792623
    [No Abstract]   [Full Text] [Related]  

  • 2. Osimertinib in Resected EGFR-Mutated NSCLC.
    Di Maio M
    N Engl J Med; 2023 Oct; 389(14):1341-1342. PubMed ID: 37792622
    [No Abstract]   [Full Text] [Related]  

  • 3. Osimertinib with Chemotherapy in EGFR-Mutated NSCLC. Reply.
    Planchard D; Jänne PA; Kobayashi K
    N Engl J Med; 2024 Feb; 390(5):478-479. PubMed ID: 38294984
    [No Abstract]   [Full Text] [Related]  

  • 4. Osimertinib with Chemotherapy in EGFR-Mutated NSCLC.
    van Waalwijk van Doorn-Khosrovani SB; Badrising SK; Burgers S
    N Engl J Med; 2024 Feb; 390(5):478. PubMed ID: 38294983
    [No Abstract]   [Full Text] [Related]  

  • 5. L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.
    Bersanelli M; Minari R; Bordi P; Gnetti L; Bozzetti C; Squadrilli A; Lagrasta CA; Bottarelli L; Osipova G; Capelletto E; Mor M; Tiseo M
    J Thorac Oncol; 2016 Oct; 11(10):e121-3. PubMed ID: 27257132
    [No Abstract]   [Full Text] [Related]  

  • 6. Divergent
    Rehman M; Kim C; Reuss JE; Kiedrowski LA; Garg RJ; Liu SV
    JCO Precis Oncol; 2021 Nov; 5():939-942. PubMed ID: 34994624
    [No Abstract]   [Full Text] [Related]  

  • 7. Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.
    Minari R; Bordi P; La Monica S; Squadrilli A; Leonetti A; Bottarelli L; Azzoni C; Lagrasta CAM; Gnetti L; Campanini N; Petronini PG; Alfieri R; Tiseo M
    J Thorac Oncol; 2018 Jun; 13(6):e89-e91. PubMed ID: 29596911
    [No Abstract]   [Full Text] [Related]  

  • 8. Osimertinib in Resected
    Wu YL; Tsuboi M; He J; John T; Grohe C; Majem M; Goldman JW; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Hodge R; Atasoy A; Rukazenkov Y; Herbst RS;
    N Engl J Med; 2020 Oct; 383(18):1711-1723. PubMed ID: 32955177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC.
    Yan Y; Jiang G; Ma W; Li T; Wang L
    Clin Lung Cancer; 2020 Nov; 21(6):562-567. PubMed ID: 32622727
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.
    Okuno T; Arakawa S; Yoshida T; Ohe Y
    Lung Cancer; 2020 May; 143():95-96. PubMed ID: 32209253
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.
    Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C
    Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient With Stage IV NSCLC and CNS Metastasis With EGFR Exon 18-25 Kinase Domain Duplication With Response to Osimertinib as a First-Line Therapy.
    Taek Kim J; Zhang W; Lopategui J; Vail E; Balmanoukian A
    JCO Precis Oncol; 2021 Nov; 5():88-92. PubMed ID: 34994592
    [No Abstract]   [Full Text] [Related]  

  • 13. Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC.
    Zhao B; Yao L; Ma W
    J Thorac Oncol; 2024 May; 19(5):e5-e6. PubMed ID: 38719426
    [No Abstract]   [Full Text] [Related]  

  • 14. Osimertinib confers potent binding affinity to EGFR kinase domain duplication.
    Jin R; Li J; Jin Z; Lu Y; Shao YW; Li W; Zhao G; Xia Y
    Int J Cancer; 2019 Nov; 145(10):2884-2885. PubMed ID: 31393596
    [No Abstract]   [Full Text] [Related]  

  • 15. Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib.
    Kuo CS; Huang CH; Liu CY; Pavlidis S; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
    Target Oncol; 2019 Aug; 14(4):433-440. PubMed ID: 31346928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC".
    Chen CY; Wang GS; Wei JC
    J Thorac Oncol; 2024 May; 19(5):e6-e7. PubMed ID: 38719427
    [No Abstract]   [Full Text] [Related]  

  • 17. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients.
    Remon J; Steuer CE; Ramalingam SS; Felip E
    Ann Oncol; 2018 Jan; 29(suppl_1):i20-i27. PubMed ID: 29462255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
    van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
    Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Giustini NP; Pritchard CC; Kamat NV; Menon MP
    JCO Precis Oncol; 2024 Jul; 8():e2300215. PubMed ID: 38991179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer.
    Zhu C; You YH; Nie KK; Ji YX
    Chin Med J (Engl); 2019 May; 132(9):1115-1116. PubMed ID: 31033571
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.